NMS-P118

Catalog No.S8363 Batch:S836302

Technical Data

Formula	C₂₀H₂₄F₃N₃O₂
Molecular Weight	395.42	CAS No.	1262417-51-5
Solubility (25°C)*	In vitro	DMSO	79 mg/mL (199.78 mM)
		Ethanol	10 mg/mL (25.28 mM)
		Water	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations. * Room temperature shipping (Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Biological Activity

Description

NMS-P118 is a potent, orally available, and highly selective PARP-1 inhibitor endowed with excellent ADME and pharmacokinetic profiles, showing 150-fold selectivity for PARP-1 over PARP-2 (Kd 0.009 μM vs 1.39 μM, respectively).

Targets

PARP1 ^[1]
(Cell-free assay)

0.009 μM(Kd)

In vitro

NMS-P118 is a potent (KD = 0.009 μM) PARP-1 inhibitor, showing 150-fold selectivity over PARP-2 (KD = 1.39 μM). The compound shows high solubility and permeability^[1].

In vivo

NMS-P118 is proved to be metabolically stable, it modestly inhibits two cytochrome P450 family members (CYP-2B6 IC50, 8.15 μM; CYP-2D6 IC50, 9.51 μM) out of eight isoforms tested. NMS-P118 has low in vivo clearance, and complete oral bioavailability. The pharmacokinetic profile of NMS-P118 in rat dosed iv at 10 mg/kg and orally at 10 and 100 mg/kg, mirrors that observed in the mouse, with oral bioavailability >65%, and linearity of exposure with dose. Its treatment dramatically decreases intratumoral PAR levels at 1, 2, and 6 h after administration and partial recovery of PAR levels is observed at 24 h. NMS-P118 shows excellent ADME and pharmacokinetic profiles, high oral availability in the mouse and rat, and high efficacy both as a single agent and in combination with Temozolomide in BRCA1-mutated MDA-MB-436 and BRCA2 deficient Capan-1 human tumor xenograft models, respectively^[1].

Protocol (from reference)

Cell Assay:^{^[1]}	Cell lines HeLa cells Concentrations -- Incubation Time 30 mins Method 6000 cells/well are seeded in 96-well plates in MEM/10% FCS and incubated for 24 h at 37℃, 5% carbon dioxide. Test compounds are then added at the required concentration for 30 min. DNA damage is then induced by adding hydrogen peroxide at the concentration of 0.1 mM for 15 min. Concentration curves are prepared in MEM/10% FCS from compound stocks in DMSO, and final DMSO concentration is 0.002% (v/v). Duplicate wells for each concentration point are prepared with a typical highest compound concentration of 20 μM and serial dilution 1:3. Plates are dried and fixed by adding cold methanol−acetone (70:30) solution for 15 min at room temperature, fixing solution is aspired, and wells are air-dried for 5 min and then dehydrated in PBS. Nonspecific binding sites are blocked by incubating wells for 30 min in PBS containing 5% (w/v) FBS 0.05% Tween 20. Wells are then incubated for 1 h at room temperature in PBS containing anti-PAR mouse monoclonal antibody diluted 1:200 in blocking solution. After three washes in PBS, wells incubate in PBS (w/v) 5% FBS 0.05% Tween 20 containing 2 μg/mL Cy2-conjugated Goat anti-mouse secondary antibody and 1 μg/mL DAPI. After washing further three times in PBS, cellular PAR immunoreactivity is assessed.
Animal Study:^{^[1]}	Animal Models Balb, Nu/Nu mice Dosages 10 mg/kg Administration i.v.

Cell Assay:^{^[1]}

Cell lines
HeLa cells
Concentrations
--
Incubation Time
30 mins
Method
6000 cells/well are seeded in 96-well plates in MEM/10% FCS and incubated for 24 h at 37℃, 5% carbon dioxide. Test compounds are then added at the required concentration for 30 min. DNA damage is then induced by adding hydrogen peroxide at the concentration of 0.1 mM for 15 min. Concentration curves are prepared in MEM/10% FCS from compound stocks in DMSO, and final DMSO concentration is 0.002% (v/v). Duplicate wells for each concentration point are prepared with a typical highest compound concentration of 20 μM and serial dilution 1:3. Plates are dried and fixed by adding cold methanol−acetone (70:30) solution for 15 min at room temperature, fixing solution is aspired, and wells are air-dried for 5 min and then dehydrated in PBS. Nonspecific binding sites are blocked by incubating wells for 30 min in PBS containing 5% (w/v) FBS 0.05% Tween 20. Wells are then incubated for 1 h at room temperature in PBS containing anti-PAR mouse monoclonal antibody diluted 1:200 in blocking solution. After three washes in PBS, wells incubate in PBS (w/v) 5% FBS 0.05% Tween 20 containing 2 μg/mL Cy2-conjugated Goat anti-mouse secondary antibody and 1 μg/mL DAPI. After washing further three times in PBS, cellular PAR immunoreactivity is assessed.

Animal Study:^{^[1]}

Animal Models
Balb, Nu/Nu mice
Dosages
10 mg/kg
Administration
i.v.

References

[1] Papeo G, et al. J Med Chem. 2015, 58(17):6875-98.

Selleck's NMS-P118 has been cited by 7 publications

Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells [ Res Sq, 2023, rs.3.rs-2688694]	PubMed: 37066268
Haploinsufficiency of ZNF251 causes DNA-PKcs-dependent resistance to PARP inhibitors in BRCA1-mutated cancer cells [ Res Sq, 2023, rs.3.rs-2688694]	PubMed: 37066268
Poly (ADP-ribose) polymerase 1 (PARP1) inhibition promotes pulmonary metastasis of osteosarcoma by boosting ezrin phosphorylation [ Int J Biol Sci, 2022, 18(3):1238-1253]	PubMed: 35173550
CRISPR screening identifies novel PARP inhibitor classification based on distinct base excision repair pathway dependencies [ bioRxiv, 2021, 10.1101/2020.10.18.333070]	PubMed: None
Response of Breast Cancer Cells to PARP Inhibitors Is Independent of BRCA Status. [ J Clin Med, 2020, 30;9(4)]	PubMed: 32235451
Enabling drug discovery for the PARP protein family through the detection of mono-ADP-ribosylation [ Biochem Pharmacol, 2019, 10.1016/j.bcp.2019.05.007]	PubMed: 31075269
DNA‑PKcs PARylation regulates DNA‑PK kinase activity in the DNA damage response. [ Mol Med Rep, 2019, 20(4):3609-3616]	PubMed: 31485633

RETURN POLICY
Selleck Chemical’s Unconditional Return Policy ensures a smooth online shopping experience for our customers. If you are in any way unsatisfied with your purchase, you may return any item(s) within 7 days of receiving it. In the event of product quality issues, either protocol related or product related problems, you may return any item(s) within 365 days from the original purchase date. Please follow the instructions below when returning products.

SHIPPING AND STORAGE
Selleck products are transported at room temperature. If you receive the product at room temperature, please rest assured, the Selleck Quality Inspection Department has conducted experiments to verify that the normal temperature placement of one month will not affect the biological activity of powder products. After collecting, please store the product according to the requirements described in the datasheet. Most Selleck products are stable under the recommended conditions.

NOT FOR HUMAN, VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.